Summary
This international observational analysis evaluated the efficacy and safety of atezolizumab, a PD-L1 checkpoint inhibitor, in patients with platinum-treated urothelial carcinoma, with outcomes stratified by prior treatment history. The study appears to have examined whether prior treatment burden (number of previous regimens) influenced response to atezolizumab therapy. As suggested by the study design and journal scope, the work contributes to understanding immunotherapy outcomes in a heavily pretreated oncology population.
UK applicability
The findings are relevant to UK cancer treatment pathways, as atezolizumab is approved by NICE for urothelial carcinoma, and understanding outcomes by prior treatment history informs patient selection and sequencing of therapies in National Health Service practice.
Key measures
Overall response rate, duration of response, progression-free survival, overall survival, stratified by number of prior chemotherapy regimens
Outcomes reported
The study examined clinical outcomes (response rates, overall survival, progression-free survival) in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab, stratified by prior treatment regimen history.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.